AKEBIA THERAPEUTICS, INC. Selling, General and Administrative Expense
AKEBIA THERAPEUTICS, INC. (AKBA) reported Selling, General and Administrative Expense of $28.17 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $28.17M, a 6.09% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $30.44M, a 18.23% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $26.09M, a 5.73% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $29.09M, a 9.72% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2025 was $107.48M, a 0.88% increase from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2024 was $106.55M, a 6.30% increase from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2023 was $100.23M, a 27.68% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2022 was $138.60M, a 20.41% decline from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $28.17M 10-Q · filed 2026-08-05 | $58.61M 10-Q · filed 2026-08-05 | $84.70M derived: sum of 3 quarters · filed 2026-08-05 | $113.79M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $30.44M 10-Q · filed 2026-05-07 | $56.52M derived: sum of 2 quarters · filed 2026-05-07 | $85.62M derived: sum of 3 quarters · filed 2026-05-07 | $112.17M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $26.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $55.18M derived: sum of 2 quarters · filed 2026-02-26 | $81.74M derived: sum of 3 quarters · filed 2026-08-05 | $107.48M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $29.09M 10-Q · filed 2025-11-10 | $55.65M derived: sum of 2 quarters · filed 2026-08-05 | $81.39M 10-Q · filed 2025-11-10 | $109.07M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $26.55M 10-Q · filed 2026-08-05 | $52.30M 10-Q · filed 2026-08-05 | $79.97M derived: sum of 3 quarters · filed 2026-08-05 | $106.49M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $25.74M 10-Q · filed 2026-05-07 | $53.42M derived: sum of 2 quarters · filed 2026-05-07 | $79.93M derived: sum of 3 quarters · filed 2026-05-07 | $106.85M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $27.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $54.19M derived: sum of 2 quarters · filed 2026-02-26 | $81.11M derived: sum of 3 quarters · filed 2026-02-26 | $106.55M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $26.52M 10-Q · filed 2025-11-10 | $53.43M derived: sum of 2 quarters · filed 2025-11-10 | $78.87M 10-Q · filed 2025-11-10 | $104.31M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $26.92M 10-Q · filed 2025-08-07 | $52.35M 10-Q · filed 2025-08-07 | $77.79M derived: sum of 3 quarters · filed 2026-02-26 | $100.50M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $25.44M 10-Q · filed 2025-05-08 | $50.87M derived: sum of 2 quarters · filed 2026-02-26 | $73.58M derived: sum of 3 quarters · filed 2026-02-26 | $100.62M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $25.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $48.15M derived: sum of 2 quarters · filed 2026-02-26 | $75.18M derived: sum of 3 quarters · filed 2026-02-26 | $100.23M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $22.71M 10-Q · filed 2024-11-07 | $49.75M derived: sum of 2 quarters · filed 2024-11-07 | $74.80M 10-Q · filed 2024-11-07 | $104.71M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $27.04M 10-Q · filed 2024-08-08 | $52.09M 10-Q · filed 2024-08-08 | $82.00M derived: sum of 3 quarters · filed 2024-08-08 | $113.88M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $25.05M 10-Q · filed 2024-05-09 | $25.22M 10-Q · filed 2023-05-08 | $54.96M derived: sum of 2 quarters · filed 2024-05-09 | $86.85M derived: sum of 3 quarters · filed 2024-05-09 | $119.09M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $29.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $61.80M derived: sum of 2 quarters · filed 2024-03-14 | $94.03M derived: sum of 3 quarters · filed 2024-03-14 | $138.60M 10-K · filed 2024-03-14 | $138.70M 10-K · filed 2023-03-10 | |||
| 2022-09-30 | $31.89M 10-Q · filed 2023-11-08 | $30.92M 10-Q · filed 2022-11-03 | $64.13M derived: sum of 2 quarters · filed 2023-11-08 | $108.69M 10-Q · filed 2023-11-08 | $108.05M 10-Q · filed 2022-11-03 | $153.50M derived: sum of 4 quarters · filed 2023-11-08 | ||
| 2022-06-30 | $32.24M 10-K/A · filed 2023-08-28 | $32.81M 10-Q · filed 2022-08-04 | $76.81M 10-K/A · filed 2023-08-28 | $77.13M 10-Q · filed 2022-08-04 | $121.61M derived: sum of 3 quarters · filed 2023-08-28 | $167.97M derived: sum of 4 quarters · filed 2023-08-28 | ||
| 2022-03-31 | $44.57M 10-K/A · filed 2023-08-28 | $44.33M 10-Q · filed 2022-05-09 | $89.37M derived: sum of 2 quarters · filed 2023-08-28 | $135.73M derived: sum of 3 quarters · filed 2023-08-28 | $177.38M derived: sum of 4 quarters · filed 2023-08-28 | |||
| 2021-12-31 | $44.80M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $91.16M derived: sum of 2 quarters · filed 2023-08-28 | $132.81M derived: sum of 3 quarters · filed 2023-08-28 | $174.14M 10-K/A · filed 2023-08-28 | $174.16M 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $46.36M 10-Q · filed 2022-11-03 | $88.01M derived: sum of 2 quarters · filed 2022-11-03 | $129.34M 10-Q · filed 2022-11-03 | $169.80M derived: sum of 4 quarters · filed 2023-08-28 | ||||
| 2021-06-30 | $41.65M 10-Q · filed 2022-08-04 | $82.98M 10-Q · filed 2022-08-04 | $123.44M derived: sum of 3 quarters · filed 2023-08-28 | $163.61M derived: sum of 4 quarters · filed 2023-08-28 | ||||
| 2021-03-31 | $41.33M 10-Q · filed 2022-05-09 | $81.79M derived: sum of 2 quarters · filed 2023-08-28 | $121.96M derived: sum of 3 quarters · filed 2023-08-28 | $157.44M derived: sum of 4 quarters · filed 2023-08-28 | ||||
| 2020-12-31 | $40.46M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $80.63M derived: sum of 2 quarters · filed 2023-08-28 | $116.12M derived: sum of 3 quarters · filed 2023-08-28 | $154.10M 10-K/A · filed 2023-08-28 | $153.95M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $40.17M 10-Q · filed 2021-11-04 | $75.65M derived: sum of 2 quarters · filed 2021-11-04 | $113.64M 10-Q · filed 2021-11-04 | $158.55M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-06-30 | $35.48M 10-Q · filed 2021-08-05 | $73.47M 10-Q · filed 2021-08-05 | $118.38M derived: sum of 3 quarters · filed 2022-03-01 | $152.56M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-03-31 | $37.98M 10-Q · filed 2021-05-10 | $82.90M derived: sum of 2 quarters · filed 2022-03-01 | $117.08M derived: sum of 3 quarters · filed 2022-03-01 | $153.15M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | $44.92M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $79.10M derived: sum of 2 quarters · filed 2022-03-01 | $115.16M derived: sum of 3 quarters · filed 2022-03-01 | $149.46M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $34.18M 10-Q · filed 2020-11-05 | $70.25M derived: sum of 2 quarters · filed 2020-11-05 | $104.54M 10-Q · filed 2020-11-05 | $159.66M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $36.07M 10-Q · filed 2020-08-10 | $70.36M 10-Q · filed 2020-08-10 | $125.48M derived: sum of 3 quarters · filed 2021-02-25 | $135.86M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | $34.29M 10-Q · filed 2020-05-05 | $89.41M derived: sum of 2 quarters · filed 2021-02-25 | $99.79M derived: sum of 3 quarters · filed 2021-02-25 | $112.33M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | $55.12M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $65.50M derived: sum of 2 quarters · filed 2021-02-25 | $78.04M derived: sum of 3 quarters · filed 2021-02-25 | $87.06M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $10.38M 10-Q · filed 2019-11-12 | $22.92M derived: sum of 2 quarters · filed 2019-11-12 | $31.94M 10-Q · filed 2019-11-12 | |||||
| 2018-06-30 | $12.54M 10-Q · filed 2019-08-08 | $21.56M 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | $9.02M 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | $27.01M 10-K · filed 2020-03-12 | |||||||
| 2016-12-31 | $22.21M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |